It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SCYX’s FA Score shows that 0 FA rating(s) are green whileTXMD’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SCYX’s TA Score shows that 4 TA indicator(s) are bullish while TXMD’s TA Score has 2 bullish TA indicator(s).
SCYX (@Pharmaceuticals: Other) experienced а -8.94% price change this week, while TXMD (@Pharmaceuticals: Other) price change was -3.64% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.23%. For the same industry, the average monthly price growth was +2.88%, and the average quarterly price growth was -9.56%.
SCYX is expected to report earnings on May 08, 2025.
TXMD is expected to report earnings on Feb 20, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
SCYX | TXMD | SCYX / TXMD | |
Capitalization | 55.9M | 24.3M | 230% |
EBITDA | 70.9M | 52.6M | 135% |
Gain YTD | -7.438 | 23.256 | -32% |
P/E Ratio | 1.06 | 0.47 | 224% |
Revenue | 140M | 69.4M | 202% |
Total Cash | 74.4M | 10.2M | 729% |
Total Debt | 15.1M | 8.2M | 184% |
SCYX | TXMD | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 70 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 49 Fair valued | 46 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 93 | |
PRICE GROWTH RATING 1..100 | 64 | 91 | |
P/E GROWTH RATING 1..100 | 99 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TXMD's Valuation (46) in the Pharmaceuticals Generic industry is in the same range as SCYX (49) in the Pharmaceuticals Other industry. This means that TXMD’s stock grew similarly to SCYX’s over the last 12 months.
TXMD's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as SCYX (100) in the Pharmaceuticals Other industry. This means that TXMD’s stock grew similarly to SCYX’s over the last 12 months.
TXMD's SMR Rating (93) in the Pharmaceuticals Generic industry is in the same range as SCYX (97) in the Pharmaceuticals Other industry. This means that TXMD’s stock grew similarly to SCYX’s over the last 12 months.
SCYX's Price Growth Rating (64) in the Pharmaceuticals Other industry is in the same range as TXMD (91) in the Pharmaceuticals Generic industry. This means that SCYX’s stock grew similarly to TXMD’s over the last 12 months.
SCYX's P/E Growth Rating (99) in the Pharmaceuticals Other industry is in the same range as TXMD (100) in the Pharmaceuticals Generic industry. This means that SCYX’s stock grew similarly to TXMD’s over the last 12 months.
SCYX | TXMD | |
---|---|---|
RSI ODDS (%) | 5 days ago90% | 5 days ago81% |
Stochastic ODDS (%) | 5 days ago90% | 5 days ago67% |
Momentum ODDS (%) | 5 days ago80% | 5 days ago84% |
MACD ODDS (%) | 5 days ago89% | 5 days ago88% |
TrendWeek ODDS (%) | 5 days ago89% | 5 days ago87% |
TrendMonth ODDS (%) | 5 days ago89% | 5 days ago85% |
Advances ODDS (%) | 17 days ago80% | N/A |
Declines ODDS (%) | 5 days ago90% | 5 days ago89% |
BollingerBands ODDS (%) | 5 days ago90% | 5 days ago88% |
Aroon ODDS (%) | 5 days ago90% | 5 days ago84% |
A.I.dvisor tells us that SCYX and TXMD have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and TXMD's prices will move in lockstep.
Ticker / NAME | Correlation To SCYX | 1D Price Change % | ||
---|---|---|---|---|
SCYX | 100% | -1.75% | ||
TXMD - SCYX | 29% Poorly correlated | +1.92% | ||
CURLF - SCYX | 23% Poorly correlated | +10.22% | ||
CRON - SCYX | 23% Poorly correlated | +1.02% | ||
AQST - SCYX | 23% Poorly correlated | +0.32% | ||
AMPH - SCYX | 22% Poorly correlated | +0.11% | ||
More |
A.I.dvisor tells us that TXMD and SCYX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TXMD and SCYX's prices will move in lockstep.
Ticker / NAME | Correlation To TXMD | 1D Price Change % | ||
---|---|---|---|---|
TXMD | 100% | +1.92% | ||
SCYX - TXMD | 30% Poorly correlated | -1.75% | ||
ASRT - TXMD | 27% Poorly correlated | +2.83% | ||
RMTI - TXMD | 22% Poorly correlated | +0.95% | ||
OPTN - TXMD | 21% Poorly correlated | +5.80% | ||
CTLT - TXMD | 21% Poorly correlated | N/A | ||
More |